NIH-funded research R15 grant

Activating a key enzyme to improve metabolic diseases

Official title: Pyruvate Dehydrogenase Complex Activation as a Strategy to Ameliorate Metabolic Disease

Funded at University of Nebraska Kearney · NIH-10795189 · Data updated 2026-11-12

This study is looking at how boosting a specific enzyme can help people with type 2 diabetes and heart disease by improving how their bodies use sugar, with the hope of finding new ways to make them feel better.

Quick facts

Grant typeR15 grant
Study typeNIH-funded research
Funding institutionUniversity of Nebraska Kearney
NIH-funded
Lab location1 site (Kearney, United States)
Project startSeptember 20, 2023
Project endAugust 31, 2026
Funding year2023
Award (this year)$402,782
NIH project number1R15GM152925-01
Project IDNIH-10795189 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research include individuals diagnosed with type 2 diabetes, heart disease, or related metabolic disorders.

Less likely to help

Patients with metabolic diseases not related to PDC dysfunction or those who do not have type 2 diabetes or heart disease may not benefit from this research.

What this research studies

This research investigates how activating the pyruvate dehydrogenase complex (PDC) can help treat metabolic diseases like type 2 diabetes and heart disease. The approach focuses on enhancing the activity of PDC by targeting specific inhibitors and activators, which could restore normal glucose utilization in cells. By exploring the effects of reactive oxygen species and other metabolic factors, the research aims to develop new therapeutic strategies that could improve patient outcomes. Patients may benefit from a better understanding of how their metabolism can be adjusted to combat these diseases.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that significantly improve metabolic health for patients with diabetes and heart disease.

How similar studies have gone: While the activation of PDC has been explored in some contexts, this specific approach focusing on both inhibitors and activators is relatively novel and has not been extensively tested.

Where this research is happening

  • University of Nebraska Kearney
    Kearney, United States
    Active

Researchers

  • Principal investigator: Moxley, Michael a — University of Nebraska Kearney
  • Study coordinator: Moxley, Michael a

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.